Ovid Therapeutics Inc (OVID) — Cash Flow-to-Debt Ratio
Ovid Therapeutics Inc (OVID) has a Cash Flow-to-Debt Ratio of -0.51x as of December 2025, meaning its operating cash flow of $-10.41 Million could theoretically repay -1% of its total liabilities ($20.27 Million) in one year. Explore OVID strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Ovid Therapeutics Inc Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Ovid Therapeutics Inc across 12 annual periods. Also explore total assets of Ovid Therapeutics Inc for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Ovid Therapeutics Inc (2014–2025)
Year-by-year debt coverage analysis for Ovid Therapeutics Inc. For market capitalisation and broader financial context, see Ovid Therapeutics Inc stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.89x | $-38.33 Million | $20.27 Million | ▲ +19.1% |
| 2024 | -2.34x | $-55.96 Million | $23.94 Million | ▼ -187.1% |
| 2023 | -0.81x | $-45.78 Million | $56.23 Million | ▲ +66.1% |
| 2022 | -2.40x | $-55.23 Million | $22.99 Million | ▼ -130.0% |
| 2021 | 8.02x | $118.61 Million | $14.80 Million | ▲ +601.8% |
| 2020 | -1.60x | $-51.58 Million | $32.29 Million | ▲ +66.2% |
| 2019 | -4.72x | $-51.09 Million | $10.82 Million | ▲ +8.3% |
| 2018 | -5.15x | $-45.56 Million | $8.84 Million | ▲ +1.4% |
| 2017 | -5.23x | $-31.47 Million | $6.02 Million | ▼ -9.6% |
| 2016 | -4.77x | $-17.80 Million | $3.73 Million | ▼ -100.7% |
| 2015 | -2.38x | $-5.49 Million | $2.31 Million | ▼ -9.1% |
| 2014 | -2.18x | $-261.28K | $119.95K | — |